Clinical trial
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
NCT03319940 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)
- Lead sponsor
- Amgen
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- December 26, 2017
- Completion date
- December 31, 2027
- Enrollment
- 269 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.